Related Experiment Video
Updated: Jan 5, 2026
Expression of Transgenes in Native Bladder Urothelium Using Adenovirus-Mediated Transduction
Published on: October 6, 2022
PIAS1 is not suitable as a urothelial carcinoma biomarker protein and pharmacological target
Holger Hans Hermann Erb1,2, Marlies Ebert1, Ronja Kuhn1
1Department of Urology and Pediatric Urology, University Medical Center Mainz, Mainz, Germany.
Abstract:
Urothelial cancer (UC) is one of the most common cancers in Europe and is also one of the costliest to treat. When first line therapies show initial success, around 50% of cancers relapse and proceed to metastasis. In this study we assessed the Protein inhibitor of activated signal transducers and activators of transcription (PIAS)1 as a potential therapeutic target in urothelial cancer. PIAS1 is a key regulator of STAT1 signalling and may be implicated in carcinogenesis. In contrast to other cancer types PIAS1 protein expression is not significantly different in malignant areas of UC specimens compared to non-malignant tissue. In addition, we found that down-regulation and overexpression of PIAS1 had no effect on the viability or colony forming ability of tested cell lines. Whilst other studies of PIAS1 suggest an important biological role in cancer, this study shows that PIAS1 has no influence on reducing the cytotoxic effects of Cisplatin or cell recovery after DNA damage induced by irradiation. Taken together, these in vitro data demonstrate that PIAS1 is not a promising therapeutic target in UC cancer as previously shown in different entities such as prostate cancer (PCa).
Insights
Protein inhibitor of activated signal transducers and activators of transcription (PIAS)1 is not a viable therapeutic target for urothelial cancer. This study found PIAS1 does not impact cancer cell viability or response to chemotherapy and radiation.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Urothelial cancer (UC) is a prevalent and costly malignancy, with high relapse and metastasis rates after initial treatment.
- Protein inhibitor of activated signal transducers and activators of transcription (PIAS)1 regulates STAT1 signaling and is implicated in carcinogenesis.
- Previous studies suggested PIAS1's role in various cancers, prompting investigation in UC.
Purpose of the Study:
- To evaluate PIAS1 as a potential therapeutic target in urothelial cancer.
- To determine the effect of PIAS1 expression on UC cell viability and response to DNA damage treatments.
Main Methods:
- Assessed PIAS1 protein expression in UC tissues.
- Examined the impact of PIAS1 down-regulation and overexpression on UC cell viability and colony formation.
- Investigated PIAS1's role in modulating cytotoxic effects of Cisplatin and recovery from irradiation-induced DNA damage.
Main Results:
- PIAS1 protein expression showed no significant difference between malignant and non-malignant UC tissues.
- Altering PIAS1 levels did not affect UC cell viability or colony-forming ability.
- PIAS1 did not influence the cytotoxic effects of Cisplatin or cellular recovery post-irradiation.
Conclusions:
- PIAS1 is not a promising therapeutic target for urothelial cancer.
- Unlike in other cancer types like prostate cancer, PIAS1 does not appear to play a significant role in UC progression or treatment resistance.
Related Concept Videos
01:27Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
01:19Allosteric Proteins-ATCase
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...